The effect of L-arginine supplementation on matabolic factors and stress oxidative indices in patients with Metabolic dysfunction-associated steatotic liver disease (MASLD)

The effect of L-arginine supplementation on matabolic factors and stress oxidative indices in patients with Metabolic dysfunction-associated steatotic liver disease (MASLD): a double-blind randomized controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230123057193N5

Enrollment

Registered

2024-10-29

Start date

2024-10-22

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic dysfunction-associated steatotic liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Intervention group: The intervention group will receive 3000 mg of arginine daily (3 tablets of 1000 mg) with water for 8 weeks. Arginine tablets are purchased from

Eligibility

Sex/Gender

All

Age

30 Years to 55 Years

Inclusion criteria

Inclusion criteria: Patients with metabolic disorder related to diagnosed steatotic liver disease without fibrosis and cap score below 310 and Metavir score below f1, which has been confirmed by a gastroenterologist. BMI 25- 35 Age between 30-55

Exclusion criteria

Exclusion criteria: Pregnant and lactating Chronic diseases such as cardiovascular, cancer, Alzheimer's, Parkinson's, and chronic kidney disease, history of stroke and heart attack, rheumatoid arthritis, diabetes, thyroid diseases, and other chronic diseases and menopause Based on the information provided by the individualBlood Pressure Medications Thyroid Medications Corticosteroids drug Drugs affecting blood glucose levels Anti-inflammatory supplements Antioxidant supplements Omega 3 consumption Blood Pressure Medications Taking antibiotics, antivirals and antifungals Any history of alcohol and tobacco use

Design outcomes

Primary

Measure	Time frame
Malondialdehyde. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Elisa.;Homeostatic Model Assessment for Insulin Resistance, Homeostasis Model Assessment of ß-cell function, Quantitative insulin sensitivity check index. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Using the formula.;Alanine transaminase, Aspartate aminotransferase. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Elisa.;Low density lipoprotein, High density lipoprotein, Triglyceride, Total cholesterol. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Elisa.;Fasting blood sugar, Fasting blood insulin. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Elisa.	—

Measure

Time frame

Malondialdehyde. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Elisa.;Homeostatic Model Assessment for Insulin Resistance, Homeostasis Model Assessment of ß-cell function, Quantitative insulin sensitivity check index. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Using the formula.;Alanine transaminase, Aspartate aminotransferase. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Elisa.;Low density lipoprotein, High density lipoprotein, Triglyceride, Total cholesterol. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Elisa.;Fasting blood sugar, Fasting blood insulin. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Elisa.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactsorayia ebrahim pour koujan

Tehran University of Medical Sciences

nutri.seam1@gmail.com+98 21 5563 0553

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026